Secondary pooled analysis of two phase 3 trials (851 patients with moderate-to-severe atopic dermatitis): lebrikizumab beat placebo on EASI 75, itch and IGA at week 16 regardless of atopic comorbidities (72.2% had one); most responders maintained response to week 52.
Secondary analysisn = 851
Sher et al. Lebrikizumab is efficacious in adults and adolescents with moderate-to-severe atopic dermatitis regardless of atopic comorbidities